Andrographis paniculata extract
AssigneeNutrition Science Partners Limited
InventorsJifeng Duan, Zhiming Ma, Xiaoqiang Yan, Weihan Zhang, Tao Wang, Yu Cai
Life of this patent
Estimating the term…
Abstract
An extract of Andrographis paniculata extract containing andrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographolide, neoandrographolide, polysacchorides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease.
Claims9
An extract of Andrographis paniculata comprising andrographolide lactones:
- wherein said andrographolide lactones comprise:
- andrographolide in an amount ranging from 2% to 20% of the dry weight of the extract;
- 14-deoxyandrographolide in an amount ranging from greater than 0 to less than 1% of the dry weight of the extract;
- 14-deoxy-11,12-dehydrogen-andrographolide in an amount ranging from 1% to 6% of the dry weight of the extract;
- and
- neoandrographolide in an amount ranging from 1% to 5% of the dry weight of the extract.
A solid dosage form for oral administration to a human to treat an inflammatory bowel disease comprising:
- (1) an extract of Andrographis paniculata comprising andrographolide lactones:
- wherein said andrographolide lactones comprise:
- andrographolide in an amount ranging from 2% to 20% of the dry weight of the extract;
- 14-deoxyandrographolide in an amount ranging from greater than 0 to less than 1% of the dry weight of the extract;
- 14-deoxy-11,12-dehydrogen-andrographolide in an amount ranging from 1% to 6% of the dry weight of the extract;
- and
- neoandrographolide in an amount ranging from 1% to 5% of the dry weight of the extract, and
- (2) wherein said solid dosage form, following said oral administration to said human, shows efficacy in treating said inflammatory bowel disease, and wherein said solid dosage form further comprises at least one pharmaceutically acceptable carrier.
A pharmaceutical composition comprising:
- (A) an extract of Andrographis paniculata comprising andrographolide lactones:
- wherein said andrographolide lactones comprise:
- andrographolide in an amount ranging from 2% to 20% of the dry weight of the extract;
- 14-deoxyandrographolide in an amount ranging from greater than 0 to less than 1% of the dry weight of the extract;
- 14-deoxy-11,12-dehydrogen-andrographolide in an amount ranging from 1% to 6% of the dry weight of the extract;
- and
- neoandrographolide in an amount ranging from 1% to 5% of the dry weight of the extract, and
- (B) at least one pharmaceutically acceptable carrier,
- wherein said pharmaceutical composition has been shown to be effective for treating ulcerative colitis in a human.
A solid dosage form for oral administration to a human to treat ulcerative colitis comprising:
- (1) an extract of Andrographis paniculata comprising andrographolide lactones:
- wherein said andrographolide lactones comprise:
- andrographolide in an amount ranging from 2% to 20% of the dry weight of the extract;
- 14-deoxyandrographolide in an amount ranging from greater than 0 to less than 1% of the dry weight of the extract;
- 14-deoxy-11,12-dehydrogen-andrographolide in an amount ranging from 1% to 6% of the dry weight of the extract;
- and
- neoandrographolide in an amount ranging from 1 to 5% of the dry weight of the extract, and
- (2) wherein said solid dosage form, following said oral administration to said human, shows efficacy in treating said ulcerative colitis, and wherein said solid dosage form further comprises at least one pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.